VASOGEN CELACADE TRIAL FAILS

Vasogen has reported that a late stage clinical trial failed to show that its experimental treatment Celacade improved walking distances in patients with peripheral artery disease.

The company had stopped the study in August 2005 after a steering committee found that the treatment was not as effective as hoped. The primary endpoint of the trial was to increase the walking distance of patients with peripheral artery disease who develop debilitating muscle pain. The condition occurs when plaque builds in the arteries and increases the risk of heart attacks and strokes.